Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis

Abatacept (CTLA-4Ig) blocks CD28-mediated T cell activation by binding to the costimulatory B7 ligands CD80/CD86 on antigen presenting cells. Costimulatory molecules, however, can also be expressed on T cells upon activation. Therefore, the aim of our study was to investigate direct effects of CTLA-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Rheumatology (Oxford, England) England), 2016-04, Vol.55 (4), p.710-720
Hauptverfasser:	Bonelli, Michael, Göschl, Lisa, Blüml, Stephan, Karonitsch, Thomas, Hirahara, Kiyoshi, Ferner, Elisabeth, Steiner, Carl-Walter, Steiner, Günter, Smolen, Josef S, Scheinecker, Clemens
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - pharmacology Abatacept - therapeutic use Antirheumatic Agents - pharmacology Antirheumatic Agents - therapeutic use Apoptosis - drug effects Apoptosis - immunology Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology CD4-Positive T-Lymphocytes - drug effects Cells, Cultured fas Receptor - immunology Female Humans Immune Tolerance - drug effects Immunophenotyping Lymphocyte Activation - drug effects Lymphocyte Activation - immunology Male Middle Aged T-Lymphocyte Subsets - drug effects T-Lymphocytes, Regulatory - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!